ArticleMolecules (Basel, Switzerland)2021
Polymeric Nanoparticles Active against Dual-Species Bacterial Biofilms.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Comprehensive insights into the role of nanocarriers in advancing azole-based ocular therapeutics.RSC advances · 2025Review
- Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects.Drug delivery and translational research · 2025Review
- Nature-Derived Gelatin-Based Antifungal Nanotherapeutics for combattingEnvironmental science. Nano · 2024Article
- Quorum Sensing in Gram-Negative Bacteria: Strategies to Overcome Antibiotic Resistance in Ocular Infections.Current molecular medicine · 2024Review
- Antimicrobial polymer-siRNA polyplexes as a dual-mode platform for the treatment of wound biofilm infections.Materials horizons · 2023Article
- Antimicrobial polymer-loaded hydrogels for the topical treatment of multidrug-resistant wound biofilm infections.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Microbial Biofilms: Applications, Clinical Consequences, and Alternative Therapies.Microorganisms · 2023Review
- Advances in Nanotechnology for Biofilm Inhibition.ACS omega · 2023Review
- Phytochemical-Based Nanomaterials against Antibiotic-Resistant Bacteria: An Updated Review.Polymers · 2023Review
- Ultrasound-Enhanced Antibacterial Activity of Polymeric Nanoparticles for Eradicating Bacterial Biofilms.Advanced healthcare materials · 2022Article
- All-natural gelatin-based bioorthogonal catalysts for efficient eradication of bacterial biofilms.Chemical science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Biofilm infections are a global public health threat, necessitating new treatment strategies. Biofilm formation also contributes to the development and spread of multidrug-resistant (MDR) bacterial strains. Biofilm-associated chronic infections typically involve colonization by more than one bacterial species. The co-existence of multiple species of bacteria in biofilms exacerbates therapeutic challenges and can render traditional antibiotics ineffective. Polymeric nanoparticles offer alternative antimicrobial approaches to antibiotics, owing to their tunable physico-chemical properties. Here, we report the efficacy of poly(oxanorborneneimide) (PONI)-based antimicrobial polymeric nanoparticles (PNPs) against multi-species bacterial biofilms. PNPs showed good dual-species biofilm penetration profiles as confirmed by confocal laser scanning microscopy. Broad-spectrum antimicrobial activity was observed, with reduction in both bacterial viability and overall biofilm mass. Further, PNPs displayed minimal fibroblast toxicity and high antimicrobial activity in an in vitro co-culture model comprising fibroblast cells and dual-species biofilms of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.